Susquehanna International Group, LLP Capricor Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.56 - $15.21 $396,228 - $1.69 Million	111,300 Added 1060.0%	121,800 $1.85 Million
Q2 2024 Aug 15, 2024	SELL	$4.63 - $7.09 $80,562 - $123,366	-17,400 Reduced 62.37%	10,500 $50,000
Q1 2024 May 07, 2024	SELL	$3.61 - $6.88 $92,055 - $175,440	-25,500 Reduced 47.75%	27,900 $189,000
Q4 2023 Feb 14, 2024	SELL	$2.71 - $5.08 $18,157 - $34,036	-6,700 Reduced 11.15%	53,400 $261,000
Q3 2023 Nov 14, 2023	BUY	$3.42 - $7.85 $167,238 - $383,865	48,900 Added 436.61%	60,100 $205,000
Q2 2023 Aug 11, 2023	SELL	$3.76 - $5.05 $19,552 - $26,260	-5,200 Reduced 31.71%	11,200 $53,000
Q1 2023 May 16, 2023	SELL	$3.78 - $5.03 $361,368 - $480,868	-95,600 Reduced 85.36%	16,400 $69,000
Q4 2022 Feb 14, 2023	SELL	$3.36 - $6.55 $135,408 - $263,965	-40,300 Reduced 26.46%	112,000 $432,000
Q3 2022 Nov 14, 2022	SELL	$3.61 - $6.08 $1,805 - $3,040	-500 Reduced 0.33%	152,300 $914,000

8.13M

1.78M

1.4M

Ticker CAPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,346,200
Market Cap $338M
Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.